Stay updated on Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial page.

Latest updates to the Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedPlain Language Summary has been added to the Study Details page to improve readability of the trial information. The record now shows a new revision (v3.4.2) and recent update dates (2025-12, 2026-01, 2026-02-04), replacing the previous v3.4.0.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded a glossary toggle and new data-provenance fields (Last Update Submitted that Met QC Criteria, Last Update Posted); the older QC-field label and No FEAR Act data were removed, and the site revision is now shown as Revision: v3.4.0.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now lists Revision: v3.3.4 and removes Revision: v3.3.3, indicating a minor update to the protocol/documentation. No other substantive study details such as outcomes, enrollment, or eligibility appear to be changed.SummaryDifference0.0%

- Check77 days agoChange DetectedLocation listings were updated to add numerous sites across the United States, Australia, and various other countries. Several existing sites were removed.SummaryDifference2%

- Check98 days agoChange DetectedRevision: v3.3.2 has been added. Revision: v3.3.1 has been removed.SummaryDifference0.0%

- Check105 days agoChange DetectedA note was added clarifying that publications are automatically filled from PubMed, and the page revision is updated to v3.3.1.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial page.